Risk of End-Stage Renal Disease in Patients with Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis

Arthritis and Rheumatology

Volumn 68, Issue 6, 2016, Pages 1432-1441

  Tektonidou, Maria G ^a   Dasgupta, Abhijit ^b   Ward, Michael M ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLUCOCORTICOID; MYCOPHENOLATE MOFETIL;

AFRICA; ARTICLE; ASIA; AUSTRALIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG USE; END STAGE RENAL DISEASE; EUROPE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; META ANALYSIS; NORTH AMERICA; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR; SOUTH AND CENTRAL AMERICA; SYSTEMATIC REVIEW; BAYES THEOREM; COMPLICATION; KIDNEY FAILURE, CHRONIC; RISK ASSESSMENT; TIME FACTOR;

BAYES THEOREM; HUMANS; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; RISK ASSESSMENT; TIME FACTORS;

EID: 84971218646     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39594     Document Type: Article

References (41)

1. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al., Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82: 299-308.
2. Yap DY, Tang CS, Ma MK, Lam MF, Chan TM., Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant 2012; 27: 3248-54.
3. Li T, Carls GS, Panopalis P, Wang S, Gibson TB, Goetzel RZ., Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large Medicaid population. Arthritis Rheum 2009; 61: 755-63.
4. Ward MM., Medical insurance, socioeconomic status, and age of onset of end-stage renal disease in patients with lupus nephritis. J Rheumatol 2007; 34: 2024-7.
5. Lateef A, Petri M., Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther 2012; 14 Suppl 4: S4.
6. Croca SC, Rodrigues T, Isenberg D., Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology (Oxford) 2011; 50: 1424-30.
7. Ortega LM, Schultz DR, Lenz O, Pardo V, Contreras GN., Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. Lupus 2010; 19: 557-74.
8. Appel GB, Cohen DJ, Pirani CL, Meltzer JI, Estes D., Long-term follow-up of patients with lupus nephritis: a study based on the classification of the World Health Organization. Am J Med 1987; 83: 877-85.
9. Donadio JV Jr, Hart GM, Bergstralh EJ, Holley KE., Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 1995; 4: 109-15.
10. Najafi CC, Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, et al., Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001; 59: 2156-63.
11. Felson DT, Anderson J., Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis: a pooled analysis. N Engl J Med 1984; 311: 1528-33.
12. Austin HA III, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al., Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-9.
13. Henderson L, Masson P, Craig JC, Flanc RS, Roberts MA, Strippoli GF, et al., Treatment for lupus nephritis. Cochrane Database Syst Rev 2102; 12: CD002922.
14. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al., American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64: 797-808.
15. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al., Joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-82.
16. Jurkovitz CT, Li S, Norris KC, Saab G, Bomback AS, Whaley-Connell AT, et al., Association between lack of health insurance and risk of death and ESRD: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2013; 61 Suppl 2: S24-32.
17. Faurschou M, Dreyer L, Kamper AL, Starklint H, Jacobsen S., Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res (Hoboken) 2010; 62: 873-80.
18. Ward MM., Socioeconomic status and the incidence of ESRD. Am J Kidney Dis 2008; 51: 563-72.
19. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6: e1000100.
20. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al., Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000; 283: 2008-12.
21. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al., The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. URL: http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp.
22. Guyot P, Ades AE, Ouwens MJ, Welton NJ., Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 2012; 12: 9.
23. Ward MM, Studenski S., Clinical prognostic factors in lupus nephritis: the importance of hypertension and smoking. Arch Intern Med 1992; 152: 2082-8.
24. Plummer M., rjags: Bayesian graphical models using MCMC. R package version 3-12. URL: http://CRAN.R-project.org/package=rjags.
25. World Bank. How do we classify countries? URL: http://data.worldbank.org/about/country-classifications.
26. Teo K, Lear S, Islam S, Mony P, Dehghan M, Li W, et al, on behalf of the PURE Investigators. Prevalence of a healthy lifestyle among individuals with cardiovascular disease in high-, middle-, and low-income countries: the Prospective Urban Rural Epidemiology (PURE) study. JAMA 2013; 309: 1613-21.
27. Wang PS, Aguilar-Gaxiola S, Alonso J, Angermeyer MC, Borges G, Bromet EJ, et al., Use of mental health services for anxiety, mood, and substance disorders in 17 countries in the WHO world mental health surveys. Lancet 2007; 370: 841-50.
28. Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C., Progressive improvement of patient and renal survival and reduction of morbidity over time in patients with lupus nephritis. Lupus 2013; 22: 810-8.
29. Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C., The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant 2007; 22: 2531-9.
30. Fiehn C, Hajjar Y, Mueller K, Waldherr R, Ho AD, Andrassy K., Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis 2003; 62: 435-9.
31. Ward MM., Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004. J Rheumatol 2009; 36: 63-7.
32. Esdaile JM, Abrahamowitz M, MacKenzie T, Hayslett JP, Kashgarian M., The time-dependence of long-term prediction in lupus nephritis. Arthritis Rheum 1994; 37: 359-68.
33. Ward MM., Access to care and the incidence of endstage renal disease due to systemic lupus erythematosus. J Rheumatol 2010; 37: 1158-63.
34. Petri M, Perez-Gutthann S, Longenecker JC, Hochberg M., Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med 1991; 91: 345-53.
35. Dooley MA, Hogan S, Jennette C, Falk R, for the Glomerular Disease Collaborative Network. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 1997; 51: 1188-95.
36. Alarcon GS, McGwin G Jr, Petri M, Ramsey-Goldman R, Fessler BJ, Vila LM, et al, for the PROFILE Study Group. Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort. PLoS Med 2006; 3: e396.
37. Julian LJ, Yelin E, Yazdany J, Panopalis P, Trupin L, Criswell LA, et al., Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Rheum 2009; 61: 240-6.
38. Haddiya I, Hamzaoui H, Tachfouti N, Hamany ZA, Radoui A, Zbiti N, et al., Features and outcomes of lupus nephritis in Morocco: analysis of 114 patients. Int J Nephrol Renovasc Dis 2013; 6: 249-58.
39. Ayodele OE, Okpechi IG, Swanepoel CR., Long-term renal outcome and complications in South Africans with proliferative lupus nephritis. Int Urol Nephrol 2013; 45: 1289-300.
40. Trager J, Ward MM., Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol 2001; 13: 345-51.
41. Urowitz MB, Gladman DD, Tom BD, Ibanez D, Farewell VT., Changing patterns of mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 2008; 35: 2152-8.